Compare FXNC & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FXNC | ACIU |
|---|---|---|
| Founded | 1907 | 2003 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 234.3M | 213.3M |
| IPO Year | N/A | 2016 |
| Metric | FXNC | ACIU |
|---|---|---|
| Price | $28.15 | $3.06 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 37.5K | ★ 361.1K |
| Earning Date | 01-29-2026 | 03-12-2026 |
| Dividend Yield | ★ 2.45% | N/A |
| EPS Growth | ★ 96.00 | N/A |
| EPS | ★ 1.96 | N/A |
| Revenue | ★ $86,993,000.00 | $5,482,957.00 |
| Revenue This Year | $7.52 | N/A |
| Revenue Next Year | $4.47 | $644.42 |
| P/E Ratio | $14.15 | ★ N/A |
| Revenue Growth | ★ 49.95 | N/A |
| 52 Week Low | $18.26 | $1.43 |
| 52 Week High | $27.80 | $4.00 |
| Indicator | FXNC | ACIU |
|---|---|---|
| Relative Strength Index (RSI) | 76.13 | 41.06 |
| Support Level | $25.35 | $3.18 |
| Resistance Level | $26.00 | $3.41 |
| Average True Range (ATR) | 0.59 | 0.25 |
| MACD | 0.21 | -0.06 |
| Stochastic Oscillator | 82.82 | 5.06 |
First National Corp is a bank holding company of First Bank, which is a commercial bank. Its core offering includes loans, deposits, wealth management, and other products and services. The Company operates through two reportable operating segments: Community Banking and wealth management. The Community Banking segment involves making loans and generating deposits from individuals, businesses, and charitable organizations. Wealth Management Services offers corporate trustee services, trust and estate administration, IRA administration and custody services. Key revenue is generated from Community Banking.
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.